Development of SERCA inhibitors using metabolites of metabolically engineered Physcomitrella patens as starting materials

Clinical trials of a derivative of the cytotoxin, thapsigargin, are presently performed. A positive outcome of these trials will create a increased demand for thapsigargin, which at the present only can be obtained from the plant Thapsia garganica. The goal of the project is to isolate and structural elucidate metabolites produced by genetically engineered Physcomitrella patens and to develop methods for converting these metabolites into drugs, which has affinity for the Ca²⁺ pump, which is the target for thapsigargin. The successful applicant is expected to have a strong background in synthetic chemistry and/or natural products chemistry. Experience with computational chemistry, spectroscopy and/or preparative and analytical chemistry is an advantage. The candidate must be able to work independently, but will interact with a multidisciplinary drug development oriented group.

For additional information about the project, please contact Professor Søren Brøgger Christensen, phone: +45 3533 6253, e-mail: sbc(at)farma.ku.dk.